These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29218680)

  • 41. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tardive Dyskinesia: New Treatments Available.
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 May; 57(5):11-14. PubMed ID: 31042295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Valbenazine-induced parkinsonism.
    Akbar U; Kim DS; Friedman JH
    Parkinsonism Relat Disord; 2020 Jan; 70():13-14. PubMed ID: 31785443
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tardive Dyskinesia: Treatment Update.
    Arya D; Khan T; Margolius AJ; Fernandez HH
    Curr Neurol Neurosci Rep; 2019 Aug; 19(9):69. PubMed ID: 31420757
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
    Ganz ML; Chavan A; Dhanda R; Serbin M; Yonan C
    J Med Econ; 2021; 24(1):103-113. PubMed ID: 33393412
    [TBL] [Abstract][Full Text] [Related]  

  • 47. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM; Nicewonder JA
    J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medication Options and Clinical Strategies for Treating Tardive Dyskinesia.
    Citrome LL
    J Clin Psychiatry; 2020 Jan; 81(2):. PubMed ID: 31995679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.
    Meyer JM
    CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
    Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Case Report: Valbenazine as a Treatment for Tardive Dyskinesia and Unexpected Antipsychotic Effects.
    Khurram SK; Ames M; Muniz J
    J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):220-221. PubMed ID: 33587391
    [No Abstract]   [Full Text] [Related]  

  • 53. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. VMAT2 Inhibitors in Neuropsychiatric Disorders.
    Tarakad A; Jimenez-Shahed J
    CNS Drugs; 2018 Dec; 32(12):1131-1144. PubMed ID: 30306450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database.
    Wang Q; Qu K; Du Z; Shen Y; Jiang Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):562-566. PubMed ID: 38641957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991793
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA-Approved Medications to Treat Tardive Dyskinesia.
    McEvoy JP
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.